Tag Archive for: orphan drugs

The pharma industry is facing an opportunity to overcome rare and orphan disease patient resistance and build long-term relationships through support programs specifically designed to best serve these populations and improve patient outcomes.

Without question, there has been significant progress in pinpointing treatments and accelerating rare disease diagnosis, largely due to the precision of data-driven commercial strategies and the speed of digital clinical trials.

Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them.